Literature DB >> 22829222

Liver grafts from CD39-overexpressing rodents are protected from ischemia reperfusion injury due to reduced numbers of resident CD4+ T cells.

Sandra Pommey1, Bo Lu, Jennifer McRae, John Stagg, Prue Hill, Evelyn Salvaris, Simon C Robson, Anthony J F d'Apice, Peter J Cowan, Karen M Dwyer.   

Abstract

UNLABELLED: Ischemia-reperfusion injury (IRI) is a major limiting event for successful liver transplantation, and CD4+ T cells and invariant natural killer T (iNKT) cells have been implicated in promoting IRI. We hypothesized that hepatic overexpression of CD39, an ectonucleotidase with antiinflammatory functions, will protect liver grafts after prolonged cold ischemia. CD39-transgenic (CD39tg) and wildtype (WT) mouse livers were transplanted into WT recipients after 18 hours cold storage and pathological analysis was performed 6 hours after transplantation. Serum levels of alanine aminotransferase and interleukin (IL)-6 were significantly reduced in recipients of CD39tg livers compared to recipients of WT livers. Furthermore, less severe histopathological injury was demonstrated in the CD39tg grafts. Immune analysis revealed that CD4+ T cells and iNKT cells were significantly decreased in number in the livers of untreated CD39tg mice. This was associated with a peripheral CD4+ T cell lymphopenia due to defective thymocyte maturation. To assess the relative importance of liver-resident CD4+ T cells and iNKT cells in mediating liver injury following extended cold preservation and transplantation, WT mice depleted of CD4+ T cells or mice genetically deficient in iNKT cells were used as donors. The absence of CD4+ T cells, but not iNKT cells, protected liver grafts from early IRI.
CONCLUSION: Hepatic CD4+ T cells, but not iNKT cells, play a critical role in early IRI following extended cold preservation in a liver transplant model.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22829222     DOI: 10.1002/hep.25985

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

Review 1.  Biological implications of extracellular adenosine in hepatic ischemia and reperfusion injury.

Authors:  M A Zimmerman; I Kam; H Eltzschig; A Grenz
Journal:  Am J Transplant       Date:  2013-08-07       Impact factor: 8.086

Review 2.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

Review 3.  Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.

Authors:  Maria Serena Longhi; Simon C Robson; Steven H Bernstein; Sara Serra; Silvia Deaglio
Journal:  J Mol Med (Berl)       Date:  2013-01-06       Impact factor: 4.599

4.  Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.

Authors:  Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

5.  Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.

Authors:  Yuanxing Liu; Haofeng Ji; Yu Zhang; Xiuda Shen; Feng Gao; Xiangyi He; Gabriella A Li; Ronald W Busuttil; Vijay K Kuchroo; Jerzy W Kupiec-Weglinski
Journal:  J Hepatol       Date:  2014-10-31       Impact factor: 25.083

6.  IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.

Authors:  Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

7.  CD39 overexpression does not attenuate renal fibrosis in the unilateral ureteric obstructive model of chronic kidney disease.

Authors:  Veena Roberts; B Lu; J Chia; P J Cowan; K M Dwyer
Journal:  Purinergic Signal       Date:  2016-08-26       Impact factor: 3.765

Review 8.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

9.  CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice.

Authors:  Osamu Yoshida; Shoko Kimura; Edwin K Jackson; Simon C Robson; David A Geller; Noriko Murase; Angus W Thomson
Journal:  Hepatology       Date:  2013-10-15       Impact factor: 17.425

Review 10.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.